# Goldman Sachs and Mainland Funds Back Hong Kong as Beijing Steps Up Market Support

Goldman reaffirmed a buy rating on the city's exchange operator while mainland managers built stakes in Hong Kong biotechnology during a surge in licensing deals.

- Published: 2026-07-16T05:15:30.723Z
- Canonical: https://polylog.news/2026-07-16/goldman-sachs-and-mainland-funds-back-hong-kong-as-beijing-s
- Publisher: Polylog (Global desk)
- Section: markets
- Sources: [South China Morning Post (HKEX)](https://www.scmp.com/business/markets/article/3360753/goldman-sachs-backs-hkex-buy-rating-citing-beijings-policy-support-ai-stock-boost), [South China Morning Post (biotech)](https://www.scmp.com/business/china-business/article/3360741/mainland-china-funds-increase-stakes-hong-kong-biotech-amid-surge-licensing-deals)

Capital is being directed toward Hong Kong's markets from two sources at once. Goldman Sachs reaffirmed its buy rating on Hong Kong Exchanges and Clearing, citing Beijing's policy support for the city as an international financial center and a boost from artificial-intelligence-linked stocks, in what the South China Morning Post described as a [vote of confidence in Hong Kong's financial future](https://www.scmp.com/business/markets/article/3360753/goldman-sachs-backs-hkex-buy-rating-citing-beijings-policy-support-ai-stock-boost).

At the same time, mainland Chinese institutional managers have built up positions in Hong Kong-listed biotechnology, drawn by low valuations and a surge in cross-border licensing deals. The South China Morning Post reported that China's largest mutual fund manager was among those [increasing stakes in the sector](https://www.scmp.com/business/china-business/article/3360741/mainland-china-funds-increase-stakes-hong-kong-biotech-amid-surge-licensing-deals) over the past month.

The two moves point to a deliberate effort, backed by both a Wall Street bank and mainland state-linked capital, to strengthen Hong Kong's position as the venue where Chinese growth industries raise money and where global and domestic investors meet outside the United States market.

## What this means

Beijing is using policy and mainland capital to strengthen an offshore financial hub that sits outside direct United States reach, which benefits Hong Kong's exchange operator and its listed growth sectors through higher trading volumes and valuations. The channel is deliberate state support combined with cross-border fund flows, and it advances a longer effort to build financial infrastructure that reduces dependence on New York and London. The risk is that flows this concentrated reverse quickly if policy support or the flow of licensing deals slows.

## What to watch

- The pace of biotech cross-border licensing deals, because it drives the valuations mainland funds are pursuing.
- Further Beijing measures to route capital and listings to Hong Kong, which would confirm the hub-building strategy is deepening.